FrancophonIA/ELRC3.0 huggingface dataset:
English: The identity of the patient must be matched with the essential unique patient information on the infusion bag(s) and/or outer container prior to infusion.
Slovenian: Identiteto bolnika je treba pred infundiranjem preveriti s primerjavo ključnih edinstvenih bolnikovih informacij na infuzijski vrečki/infuzijskih vrečkah in/ali zunanjem vsebniku.
English: No. of severe infections
Slovenian: Št. hudih okužb 29
English: Patients who have previously tested positive for hepatitis C can be treated with Strimvelis, provided they demonstrate absence of ongoing infection using a nucleic acid test with a limit of quantification of ≤15 international units/ml.
Slovenian: Strimvelis, če je z uporabo testa za nukleinske kisline z mejo določljivosti ≤15 IE/ml, dokazana odsotnost potekajoče okužbe.
English: Name and address of the manufacturer responsible for batch release MolMed SpA
Slovenian: Ime in naslov izdelovalca, odgovornega za sproščanje serij
English: Non-interventional PASS: In order to investigate the long term safety and efficacy of Strimvelis gene therapy, the MAH should conduct and submit the results of a long term prospective, non-interventional follow up study using data from a registry of patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) treated with Strimvelis.
Slovenian: Neintervencijska študija o varnosti zdravila po pridobitvi dovoljenja za promet: Za proučitev dolgoročne varnosti in učinkovitosti genskega zdravljenja z zdravilom Strimvelis mora MAH izvesti in predložiti rezultate dolgoročne prospektivne,
English: Strimvelis has not been studied in patients with hepatic impairment.
Slovenian: Zdravilo Strimvelis ni raziskano pri bolnikih z okvaro jeter.
English: The 3 month hospitalisation period immediately post gene therapy was excluded from the calculation d dAXP=dAMP+dADP+dATP.
Slovenian: d dAXP = dAMP + dADP + dATP.
English: The infusion bag(s) is/are placed inside a closed outer container.
Slovenian: Infuzijska vrečka/infuzijske vrečke je/so položena/položene v zaprt zunanji vsebnik.
English: Strimvelis is used to treat a serious condition called ADA-SCID (Adenosine Deaminase-Severe Combined Immune Deficiency).
Slovenian: Zdravilo Strimvelis se uporablja za zdravljenje resne motnje, hude kombinirane imunske pomanjkljivosti s pomanjkanjem adenozin deaminaze, ki jo pogosto označujejo z angleško kratico ADA-SCID (Adenosine
English: • inflamed thyroid gland (autoimmune thyroiditis)
Slovenian: • vnetje žleze ščitnice (avtoimunski tiroiditis)
English: No cases of leukaemia or myelodysplasia have been reported following treatment with Strimvelis.
Slovenian: Po zdravljenju z zdravilom Strimvelis ni bilo zabeleženih primerov levkemije ali mielodisplazije.
English: - The active substance is autologous (the patient's own) CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence.
Slovenian: - Zdravilna učinkovina je avtologna (bolniku lastna), s CD34+ obogatena celična frakcija s celicami CD34+, transduciranimi z retrovirusnim vektorjem, ki kodira zaporedje človeške ADA cDNA.
English: Asthma, rhinitis allergic
Slovenian: Bolezni dihal, prsnega koša in mediastinalnega prostora astma, alergijski rinitis
English: Time period (Years)
Slovenian: Obdobje (leta) n/a
English: Strimvelis is a type of medicine called a gene therapy.
Slovenian: Kaj je zdravilo Strimvelis in za kaj ga uporabljamo Zdravilo Strimvelis spada med zdravila, ki se uporabljajo za t. i. gensko zdravljenje.
English: Vascular disorders
Slovenian: avtoimunska trombocitopenija
English: Autoimmune hepatitis
Slovenian: Žilne bolezni hipertenzijaa
English: Also contains sodium chloride.
Slovenian: SEZNAM POMOŽNIH SNOVI Vsebuje tudi natrijev klorid.
English: x 106
Slovenian: četrtletje 2037.
English: Dispersion for infusion.
Slovenian: z infuzijo v veno.
English: Exp.: {DD MMM YY} {hh:mm} SPECIAL STORAGE CONDITIONS
Slovenian: DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA Exp.: {DD MMM LL} {hh:mm}
English: An autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human adenosine deaminase (ADA) cDNA sequence from human haematopoietic stem/progenitor (CD34+) cells.
Slovenian: 2.1 Splošen opis Avtologna, s CD34+ obogatena celična frakcija s celicami CD34+, transduciranimi z retrovirusnim vektorjem, ki kodira zaporedje človeške adenozin deaminaze (ADA) cDNA iz človeških hematopoetskih matičnih/predhodniških celic (CD34+).
English: • underactive thyroid gland (hypothyroidism)
Slovenian: • premalo dejavna žleza ščitnica (hipotiroidizem)
English: Autoimmune haemolytic anaemia, autoimmune aplastic anaemia, autoimmune thrombocytopenia
Slovenian: Bolezni krvi in limfatičnega sistema anemijaa nevtropenijaa avtoimunska hemolitična anemija, avtoimunska aplastična anemija,
English: After you (or your child) have been treated with Strimvelis, you or your child will not be able to donate blood, organs or tissues at any time in future.
Slovenian: Oseba, zdravljena z zdravilom Strimvelis, po zdravljenju nikdar več ne sme darovati krvi, organov ali tkiv,
English: Package leaflet: Information for the patient or carer Strimvelis 1-10 million cells/ml dispersion for infusion Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence
Slovenian: Navodilo za uporabo Strimvelis 1-10 milijonov celic/ml disperzija za infundiranje avtologna, s CD34+ obogatena celična frakcija s celicami CD34+, transduciranimi z retrovirusnim vektorjem,
English: Strimvelis is given…
Slovenian: Dobili boste zdravilo Strimvelis ...
English: Dermatitis atopic, eczema
Slovenian: Bolezni kože in podkožja atopijski dermatitis, ekcem
English: The most commonly reported adverse reaction was pyrexia.
Slovenian: Najpogosteje opisan neželeni učinek je bila zvišana telesna temperatura.
English: CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT Total cell number:
Slovenian: VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT Celotno število celic: x 106 celic CD34+/kg:
English: Name and address of the manufacturer of the biological active substance MolMed SpA
Slovenian: ODGOVOREN ZA SPROŠČANJE SERIJ Ime in naslov izdelovalca biološke zdravilne učinkovine
English: - If you (or your child) get any side effects, talk to your doctor or nurse.
Slovenian: - Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom ali medicinsko sestro.
English: Exp.: {DD MMM YY} {hh:mm} BATCH NUMBER, DONATION AND PRODUCT CODES
Slovenian: ŠTEVILKA SERIJE, ENOTNE OZNAKE DAROVANJA IN IZDELKOV
English: Respiratory, thoracic and mediastinal disorders
Slovenian: Bolezni jeter, žolčnika in žolčevodov avtoimunski hepatitis
English: LIST OF EXCIPIENTS
Slovenian: Št. preiskovancev
English: Not applicablee
Slovenian: POSTOPEK UPORABE
English: * Including data from one patient collected post intervention with PEG-ADA (>3 months treatment) or hematopoietic stem cell transplantation a Based on the entire pre-treatment period for severe infections (retrospectively collected), and the data collected at the baseline visit for T-lymphocytes.
Slovenian: Navedba smiselno ni potrebna * Vključno s podatki enega bolnika, zbranimi po ukrepanju s PEG-ADA (> 3 mesece zdravljenja) ali presaditvijo hematopoetskih matičnih celic.
English: Prior to launch of Strimvelis in each Member State, the Marketing Authorisation Holder (MAH) must agree about the content and format of the educational materials for parents/carers and health professionals,
Slovenian: Pred prihodom zdravila Strimvelis na trg v posamezni državi članici mora imetnik dovoljenja za promet
English: - are allergic to any of the ingredients of this medicine (listed in section 6) - have or have had a type of cancer called leukaemia or myelodysplasia - have tested positive for HIV or some other infections (your doctor will advise you about this) - have already been treated with gene therapy
Slovenian: - imate pozitiven izvid testiranja za HIV ali kakšno drugo okužbo (zdravnik vam bo dal pojasnila v zvezi s tem).
English: Paediatric population
Slovenian: Starejši bolniki
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
Slovenian: PODATKI NA ZUNANJI OVOJNINI IN PRIMARNI OVOJNINI ZUNANJI VSEBNIK
English: PHARMACEUTICAL FORM AND CONTENTS
Slovenian: FARMACEVTSKA OBLIKA IN VSEBINA disperzija za infundiranje
English: Strimvelis must not be given if you (or to your child):
Slovenian: Zdravila Strimvelis ne smete (oz. vaš otrok, če je on bolnik) dobiti, če:
English: • increases in liver enzymes*
Slovenian: • zvišanje jetrnih encimov* • rezultati preiskav krvi (pozitivni za protijedrna protitelesa)
English: (pomalidomide)
Slovenian: (pomalidomid)
English: The recommended starting dose is 4 mg once a day, taken at the same time each day.
Slovenian: Priporočeni začetni odmerek je 4 mg enkrat na dan vedno ob istem času.
English: What measures are being taken to ensure the safe and effective use of Imnovid?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Imnovid?
English: Previously known as Pomalidomide Celgene.
Slovenian: Prej znano pod imenom Pomalidomid Celgene.
English: As the medicine can pass into semen, the medicine must also not be used in men who are unable to comply with the required contraceptive measures.
Slovenian: Ker zdravilo lahko prehaja v semenčice, se zdravilo ne sme uporabljati pri moških, ki ne morejo upoštevati zahtevanih kontracepcijskih ukrepov.
English: The company that makes Imnovid will set up a pregnancy-prevention programme in each Member State.
Slovenian: Podjetje, ki trži zdravilo Imnovid, bo v vsaki državi članici vzpostavilo program za preprečevanje nosečnosti.
English: Further information on the orphan designation can be found on ema.europa.eu/medicines/human/orphan-designations/EU309672.
Slovenian: Nadaljnje informacije glede določitve zdravila sirote lahko najdete tukaj: ema.europa.eu/medicines/human/orphan-designations/EU309672
English: Imnovid is available as capsules (1, 2, 3 and 4 mg).
Slovenian: Zdravilo Imnovid je na voljo v obliki kapsul (1 mg, 2 mg, 3 mg in 4 mg).
English: Imnovid received a marketing authorisation valid throughout the EU on 5 August 2013.
Slovenian: Za zdravilo Imnovid je bilo 5. avgusta 2013 izdano dovoljenje za promet, veljavno po vsej Evropski uniji.
English: The European Medicines Agency decided that Imnovid's benefits are greater than its risks and it can be authorised for use in the EU.
Slovenian: Evropska agencija za zdravila je zaključila, da so koristi zdravila Imnovid večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: It must not be used in women who could become pregnant, unless they take all the necessary steps to ensure that they are not pregnant before treatment and that they do not become pregnant during or soon after treatment.
Slovenian: Prav tako ga ne smejo uporabljati ženske, ki bi utegnile zanositi, razen če ne ukrenejo vsega potrebnega za zagotovitev, da pred začetkom zdravljenja niso noseče, in da ne zanosijo med zdravljenjem ali neposredno po koncu tega.
English: Other information about Imnovid
Slovenian: Druge informacije o zdravilu Imnovid
English: It will also supply cards for patients to ensure that all appropriate safety measures have been taken by each patient.
Slovenian: Prav tako bo priskrbelo kartice za bolnike, s pomočjo katerih bo lahko vsak bolnik preveril, ali je upošteval vse ustrezne varnostne ukrepe.
English: As for all medicines, data on the use of Imnovid are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Imnovid stalno spremljajo.
English: What is Imnovid and what is it used for?
Slovenian: Kaj je zdravilo Imnovid in za kaj se uporablja?
English: What benefits of Imnovid have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Imnovid izkazalo v študijah?
English: What are the risks associated with Imnovid?
Slovenian: Kakšna tveganja so povezana z zdravilom Imnovid?
English: Pomalidomide is expected to be harmful to the unborn child, causing severe and life-threatening birth defects.
Slovenian: Pomalidomid naj bi bil škodljiv za nerojenega otroka, zaradi česar prihaja do resnih in smrtno nevarnih prirojenih okvar.
English: Side effects reported with Imnovid are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Imnovid, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: Why is Imnovid authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Imnovid odobreno v EU?
English: An overview of Imnovid and why it is authorised in the EU
Slovenian: Pregled zdravila Imnovid in zakaj je odobreno v EU
English: For more information about using Imnovid, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Imnovid glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: The company will also set up a registry of patients treated with Imnovid to monitor the side effects reported and whether the medicine is used for its approved indication and in compliance with the pregnancy-prevention programme.
Slovenian: Podjetje bo prav tako vzpostavilo register bolnikov, zdravljenih z zdravilom Imnovid, za spremljanje neželenih učinkov, o katerih bodo poročali, in tega, ali se zdravilo uporablja za odobreno indikacijo in v skladu s programom za preprečevanje nosečnosti.
English: The medicine packs containing Imnovid capsules will carry a warning on the risk of severe birth defects.
Slovenian: Na škatlah s kapsulami zdravila Imnovid bo opozorilo o tveganju za hude prirojene okvare.
English: Each Member State will also ensure that educational materials and patient cards are provided to prescribers and patients.
Slovenian: Poleg tega bo vsaka država članica poskrbela, da bodo zdravniki, ki bodo predpisovali zdravilo, in bolniki prejeli izobraževalno gradivo in kartice za bolnike.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Imnovid have also been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Imnovid upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: Patients treated with Imnovid, bortezomib and low-dose dexamethasone lived on average 11.2 months before their disease got worse, compared with 7.1 months for patients treated with bortezomib and low dose dexamethasone.
Slovenian: Bolniki, ki so se zdravili z zdravilom Imnovid, bortezomibom in nizkoodmernim deksametazonom, so v povprečju živeli 11,2 meseca, preden se je bolezen poslabšala, v primerjavi s 7,1 meseca pri bolnikih, zdravljenih z bortezomibom in visokoodmernim deksametazonom.
English: It will provide a letter and educational kits for healthcare workers, and brochures for patients, explaining that the medicine is expected to be harmful to the unborn child and detailing the steps needed to use the medicine safely.
Slovenian: Zdravstvenim delavcem bo priskrbelo dopis in izobraževalni komplet, bolnikom pa knjižico, v katerih bo razloženo, da je zdravilo lahko škodljivo za nerojene otroke, in ki bodo vsebovali podrobnosti o varni uporabi zdravila.
English: The Agency also noted that Imnovid's side effects were acceptable for these patients, with side effects similar to those of other medicines of this type.
Slovenian: Prav tako je ugotovila, da so neželeni učinki zdravila Imnovid za te bolnike sprejemljivi, pri čemer so neželeni učinki podobni učinkom drugih tovrstnih zdravil.
English: Treatment with Imnovid must be started and supervised by a doctor experienced in treating multiple myeloma.
Slovenian: Zdravljenje z zdravilom Imnovid mora uvesti in nadzorovati zdravnik, ki ima izkušnje z zdravljenjem diseminiranega plazmacitoma.
English: Pomalidomide works in a number of ways in multiple myeloma, similarly to other immunomodulating medicines such as lenalidomide and thalidomide: it blocks the development of tumour cells, prevents the growth of blood vessels within tumours and also stimulates some specialised cells of the immune system to attack the tumour cells.
Slovenian: Pomalidomid deluje pri diseminiranem plazmacitomu na različne načine, podobno kot drugi imunomodulatorji, kot sta lenalidomid in talidomid: preprečuje razvoj tumorskih celic, preprečuje rast krvnih žil v tumorjih in spodbuja nekatere posebne celice imunskega sistema k napadanju tumorskih celic.
English: A further study included 559 patients with multiple myeloma who had received at least one treatment including lenalidomide, and whose disease got worse during or after their last treatment.
Slovenian: V nadaljnjo študijo je bilo vključenih 559 bolnikov z diseminiranim plazmacitomom, ki so prejeli vsaj eno zdravljenje, vključno z lenalidomidom, in pri katerih se je bolezen poslabšala med zadnjim zdravljenjem ali po njem.
English: The Agency concluded that Imnovid is effective at delaying the progression of multiple myeloma in patients whose disease has not got better or has come back after previous treatment, who have very limited treatment options.
Slovenian: Ugotovila je, da je zdravilo Imnovid učinkovito pri podaljševanju obdobja do napredovanja diseminiranega plazmacitoma pri bolnikih, katerih bolezen se ni izboljšala ali se je po predhodnem zdravljenju ponovila ter ki imajo zelo omejene možnosti zdravljenja.
English: The disease worsened after 16 weeks on average in patients taking Imnovid plus low-dose dexamethasone, compared with 8 weeks in those taking high-dose dexamethasone.
Slovenian: Bolezen se je v povprečju poslabšala po 16 tednih pri bolnikih, ki so jemali zdravilo Imnovid in nizkoodmerni deksametazon, v primerjavi z osmimi tedni pri bolnikih, ki so jemali visokoodmerni deksametazon.
English: The active substance in Imnovid, pomalidomide, is an immunomodulating agent.
Slovenian: Učinkovina zdravila Imnovid, pomalidomid, je imunomodulator.
English: It is taken in the first 2 weeks of 3-week treatment cycles, when given in combination with bortezomib and dexamethasone, and in the first 3 weeks of 4-week treatment cycles when given in combination with dexamethasone only.
Slovenian: V vsakem tritedenskem ciklu zdravljenja se zdravilo jemlje prva dva tedna, kadar se daje v kombinaciji z bortezomibom in deksametazonom, ter prve tri tedne v vsakem štiritedenskem ciklu, kadar se daje v kombinaciji samo z deksametazonom.
English: It is used in combination with bortezomib (another cancer medicine) and dexamethasone (an anti-inflammatory medicine) in adults who have received at least one treatment including lenalidomide (another cancer medicine).
Slovenian: Uporablja se v kombinaciji z bortezomibom (drugim zdravilom za zdravljenje raka) in deksametazonom (protivnetnim zdravilom) pri odraslih, ki so prejeli vsaj eno zdravljenje, vključno z lenalidomidom (drugim zdravilom za zdravljenje raka).
English: Imnovid has been studied in one main study involving 455 adults with multiple myeloma whose disease did not get better or came back after previous treatments.
Slovenian: Zdravilo Imnovid so proučevali v glavni študiji, ki je vključevala 455 odraslih z diseminiranim plazmacitomom, katerih bolezen se ni izboljšala ali se je po predhodnih zdravljenjih ponovila.
English: The most common side effects with Imnovid (which affect more than 1 in 10 patients), some of which can be serious, include anaemia (low red blood cell counts), neutropenia (low white blood cell count), tiredness, thrombocytopenia (low platelet counts), fever, peripheral oedema (swelling of the limbs due to fluid retention), peripheral neuropathy (nerve damage causing tingling, pain and numbness in the hands and feet) and infections including pneumonia (infection of the lungs).
Slovenian: Najpogostejši neželeni učinki zdravila Imnovid (ki se lahko pojavijo pri več kot 1 bolniku od 10), med katerimi so lahko nekateri resni, so anemija (nizko število rdečih krvnih celic), nevtropenija (nizko število belih krvnih celic), utrujenost, trombocitopenija (nizko število trombocitov), zvišana telesna temperatura, periferni edem (otekanje okončin zaradi zadrževanja tekočine), periferna nevropatija (poškodba živca, ki povzroča mravljinčenje, bolečino in odrevenelost v rokah in stopalih) ter okužbe, vključno s pljučnico (okužbo pljuč).
English: The company will also provide final results from a study with Imnovid in combination with bortezomib and dexamethasone in patients with multiple myeloma who had received at least one treatment including lenalidomide, to confirm the medicine's effect on overall survival.
Slovenian: Podjetje bo objavilo tudi končne rezultate študije z zdravilom Imnovid v kombinaciji z bortezomibom in deksametazonom pri bolnikih z diseminiranim plazmacitomom, ki so prejeli vsaj eno zdravljenje z lenalidomidom, da bi potrdili učinek zdravila na celokupno preživetje.
English: It is also used in combination with dexamethasone in adults who have received at least two prior therapies, including both lenalidomide and bortezomib, and whose disease has worsened.
Slovenian: V kombinaciji z deksametazonom se uporablja tudi pri odraslih, ki so predhodno prejeli vsaj dve zdravljenji, vključno z lenalidomidom in bortezomibom, ter pri katerih se je bolezen poslabšala.
English: For the full list of side effects and restrictions with Imnovid, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Imnovid glejte navodilo za uporabo.
English: Multiple myeloma is rare, and Imnovid was designated an ‘orphan medicine' (a medicine used in rare diseases) on 8 October 2009.
Slovenian: Diseminirani plazmacitom je redka bolezen, zato je bilo zdravilo Imnovid 8. oktobra 2009 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
English: Further information on Imnovid can be found on the Agency's website: ema.europa.eu/en/medicines/human/EPAR/imnovid-previously-pomalidomide-celgene
Slovenian: Nadaljnje informacije o zdravilu Imnovid so na voljo na spletni strani agencije: ema.europa.eu/en/medicines/human/EPAR/imnovid-previously-pomalidomide-celgene Povzetek je bil nazadnje posodobljen 04-2019.
English: Serious side effects, which affect up to 1 in 10 patients, include blood disorders (such as neutropenia, anaemia and thrombocytopenia), lower respiratory tract infection (such as bronchitis or pneumonia), pulmonary embolism (clot in a blood vessel in the lungs), flu, and acute kidney injury.
Slovenian: Resni neželeni učinki (ki se lahko pojavijo pri največ 1 bolniku od 10) vključujejo krvne motnje (kot so nevtropenija, anemija in trombocitopenija), okužbe spodnjih dihal (kot je bronhitis ali pljučnica), pljučno embolijo (strdek v krvni žili pljuč), gripo in akutne poškodbe ledvic.
English: Imnovid plus low-dose dexamethasone was more effective than high-dose dexamethasone alone at delaying the worsening of multiple myeloma.
Slovenian: Zdravilo Imnovid je bilo v kombinaciji z nizkoodmernim deksametazonom učinkovitejše od samostojnega jemanja visokoodmernega deksametazona pri podaljšanju obdobja do poslabšanja diseminiranega plazmocitoma.
English: How is Imnovid used?
Slovenian: Kako se zdravilo Imnovid uporablja?
English: Imnovid is a cancer medicine used to treat multiple myeloma (a cancer of the bone marrow).
Slovenian: Imnovid je zdravilo za zdravljenje raka, ki se uporablja za zdravljenje diseminiranega plazmacitomoa (raka kostnega mozga).
English: Imnovid contains the active substance pomalidomide.
Slovenian: Zdravilo Imnovid vsebuje učinkovino pomalidomid.
English: Treatment with Imnovid may need to be interrupted or stopped, or the dose reduced, if the disease gets worse or certain side effects occur.
Slovenian: Če se bolezen poslabša ali se pri bolniku pojavijo nekateri neželeni učinki, bo morda treba začasno ali trajno prekiniti zdravljenje z zdravilom Imnovid ali zmanjšati odmerek.
English: Therefore, Imnovid must not be used in women who are pregnant.
Slovenian: Nosečnice zato zdravila Imnovid ne smejo jemati.
English: How does Imnovid work?
Slovenian: Kako zdravilo Imnovid deluje?